Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Myeloma Propagating Cells, Drug Resistance and Relapse.

Karadimitris A, Chaidos A, Caputo V, Goudevenou K, Ponnusamy K, Xiao X.

Stem Cells. 2015 Nov;33(11):3205-11. doi: 10.1002/stem.2199. Epub 2015 Sep 28. Review.

2.

Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone.

Pilarski LM, Mant MJ, Belch AR.

Leuk Lymphoma. 1999 Jan;32(3-4):199-210. Review.

PMID:
10037018
3.

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.

Yang WC, Lin SF.

Biomed Res Int. 2015;2015:341430. doi: 10.1155/2015/341430. Epub 2015 Nov 16. Review.

4.

Advances in the biology and treatment of multiple myeloma.

Varterasian ML.

Curr Opin Oncol. 1999 Jan;11(1):3-8. Review.

PMID:
9914870
5.

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review).

Krishnan SR, Jaiswal R, Brown RD, Luk F, Bebawy M.

Int J Oncol. 2016 Jul;49(1):33-50. doi: 10.3892/ijo.2016.3516. Epub 2016 May 11. Review.

PMID:
27175906
6.

Getting to the root of the problem: the causes of relapse in multiple myeloma.

Chan Chung KC, Tiedemann RE.

Expert Rev Anticancer Ther. 2014 Mar;14(3):251-4. doi: 10.1586/14737140.2014.868776. Epub 2014 Jan 8.

PMID:
24397833
7.

Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.

Laursen MB, Falgreen S, Bødker JS, Schmitz A, Kjeldsen MK, Sørensen S, Madsen J, El-Galaly TC, Bøgsted M, Dybkær K, Johnsen HE; Myeloma Stem Cell Network.

Exp Hematol. 2014 Nov;42(11):927-38. doi: 10.1016/j.exphem.2014.07.263. Epub 2014 Jul 27. Review.

PMID:
25072621
8.

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.

Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P; European Myeloma Network.

Leukemia. 2011 May;25(5):749-60. doi: 10.1038/leu.2011.3. Epub 2011 Feb 4.

PMID:
21293488
9.

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.

Nat Rev Cancer. 2007 Aug;7(8):585-98. Review.

PMID:
17646864
10.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

11.

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.

Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo C, Vanden Berghe W, Cuendet M.

Clin Epigenetics. 2017 Feb 10;9:17. doi: 10.1186/s13148-017-0319-5. eCollection 2017. Review.

12.
13.

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.

Moreau P, Cavallo F, Leleu X, Hulin C, Amiot M, Descamps G, Facon T, Boccadoro M, Mignard D, Harousseau JL.

Leukemia. 2011 May;25(5):872-4. doi: 10.1038/leu.2011.4. Epub 2011 Feb 15. No abstract available.

PMID:
21321571
14.

The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.

Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C.

Mol Cancer Ther. 2010 Jun;9(6):1574-82. doi: 10.1158/1535-7163.MCT-10-0104. Epub 2010 Jun 1.

15.

Recent advances and future directions in targeting the secretory apparatus in multiple myeloma.

Auner HW, Cenci S.

Br J Haematol. 2015 Jan;168(1):14-25. doi: 10.1111/bjh.13172. Epub 2014 Oct 9. Review.

PMID:
25296649
16.

Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers.

Pilarski LM, Yatscoff RW, Murphy GF, Belch AR.

Leukemia. 1998 Apr;12(4):505-9.

PMID:
9557608
17.

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, Adamczyk-Cioch M, Jawniak D, Legiec W, Morawska M, Kozinska J, Waciński P, Dmoszynska A.

Ann Hematol. 2011 Oct;90(10):1161-6. doi: 10.1007/s00277-011-1276-2. Epub 2011 Jun 23.

19.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM).

Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.

20.

Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.

Trepel M, Martens V, Doll C, Rahlff J, Gösch B, Loges S, Binder M.

PLoS One. 2012;7(2):e31998. doi: 10.1371/journal.pone.0031998. Epub 2012 Feb 22.

Supplemental Content

Support Center